Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm

Artiva Biotherapeutics is hoping its NK cell therapy approach, which uses un-engineered cells, will prove effective in both oncologic and autoimmune indications and safe enough to be given in the community setting.

3d,Rendering,Of,A,Nk,Cell,(natural,Killer,Cell),Destroying
Natural killer cell destroying a cancer cell (Shutterstock)

In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications.

More from Innovation

HealthTech Innovation Versus Clinician And System Awareness

 
• By 

Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.

Podcast: Meet Grace, The Clinical Trial AI Agent

 
• By 

In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based AI agent to streamline clinical trial processes.

Barcelona Health Hub: Where Digital Health Innovation Meets Historic Art Nouveau

 
• By 

The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By 

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

More from Leadership